Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MACK
3076
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $438K | ﹤0.01% |
29,628
| – | – |
|
|
EVBN
3077
DELISTED
Evans Bancorp Inc
EVBN
| $436K | ﹤0.01% |
14,609
| – | – |
|
3078
EVI Industries
EVI
$184M
| $434K | ﹤0.01% |
17,425
+3,856
| +28% | +$84.7K |
|
3079
iShares Gold Trust
IAU
$62.7B
| $433K | ﹤0.01% |
10,318
-6,049,905
| -100% | -$237M |
|
3080
Quad
QUAD
$547M
| $433K | ﹤0.01% |
81,471
| – | – |
|
3081
Lexeo Therapeutics
LXEO
$325M
| $429K | ﹤0.01% |
+27,361
| New | +$428K |
|
3082
Invesco Dividend Achievers ETF
PFM
$793M
| $428K | ﹤0.01% |
10,058
-502
| -5% | -$20.6K |
|
3083
ClearPoint Neuro
CLPT
$463M
| $427K | ﹤0.01% |
62,770
| – | – |
|
3084
C&F Financial
CFFI
$268M
| $427K | ﹤0.01% |
8,710
| – | – |
|
3085
ProKidney
PROK
$314M
| $426K | ﹤0.01% |
259,812
+4,709
| +2% | +$6.92K |
|
3086
BCB Bancorp
BCBP
$167M
| $426K | ﹤0.01% |
40,753
-1,800
| -4% | -$20.6K |
|
3087
Ranger Energy Services
RNGR
$376M
| $425K | ﹤0.01% |
37,668
-2,837
| -7% | -$29.5K |
|
3088
Fox Class B
FOX
$22.1B
| $424K | ﹤0.01% |
14,804
+3,536
| +31% | +$98.9K |
|
3089
inTEST
INTT
$173M
| $423K | ﹤0.01% |
31,888
| – | – |
|
3090
Caledonia Mining Corp
CMCL
$362M
| $421K | ﹤0.01% |
38,017
| – | – |
|
|
ESSA
3091
DELISTED
ESSA Bancorp
ESSA
| $420K | ﹤0.01% |
23,046
| – | – |
|
3092
Biglari Holdings Class B
BH
$1.24B
| $418K | ﹤0.01% |
2,203
| – | – |
|
3093
Tilly's
TLYS
$122M
| $414K | ﹤0.01% |
60,909
| – | – |
|
3094
Bankwell Financial Group
BWFG
$550M
| $414K | ﹤0.01% |
15,956
| – | – |
|
3095
SoundThinking
SSTI
$102M
| $412K | ﹤0.01% |
25,923
| – | – |
|
3096
BioAtla
BCAB
$5.66M
| $411K | ﹤0.01% |
2,391
| – | – |
|
|
TEAD
3097
Teads Holding Co
TEAD
$76.6M
| $411K | ﹤0.01% |
104,063
| – | – |
|
3098
Waldencast
WALD
$224M
| $411K | ﹤0.01% |
63,202
-20,002
| -24% | -$154K |
|
3099
Aldeyra Therapeutics
ALDX
$91.7M
| $410K | ﹤0.01% |
125,525
| – | – |
|
3100
Eos Energy Enterprises
EOSE
$1.29B
| $410K | ﹤0.01% |
397,914
+102,858
| +35% | +$105K |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.